Physician profile
Carl Woods
NPI 1174550727
$3,339.60
in general payments reported to CMS, 2019-2025
21 companies · $61.26 in 2025
The $61.26 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $319 · 2021: $854 · 2022: $651 · 2023: $311 · 2024: $34.20 · 2025: $61.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,531.84 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $461.98 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $360.45 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $130.40 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.62 | 2019-2022 | |
| Braintree Laboratories, INC. | $104.11 | 2019-2023 | Suflave |
| Intercept Pharmaceuticals, INC. | $88.15 | 2019-2022 | |
| Evoke Pharma, INC. | $85.24 | 2021-2023 | Gimoti |
| Redhill Biopharma INC. | $67.99 | 2021 | |
| Daiichi Sankyo INC. | $64.91 | 2019-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $49.60 | 2019 | |
| Ucb, INC. | $42.27 | 2019-2020 | |
| Boston Scientific Corporation | $42.16 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $37.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.94 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.93 | 2023 | Cyltezo |
| Allergan, INC. | $22.51 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.72 | 2021 | |
| Dova Pharmaceuticals | $13.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.94 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.